SNY
Sanofi SA
$43.76
▼ 0.5%Updated Today 12:18 PM ET
SNY at a glance — five pillars scored 0–100 from real filed financials.
Overall: Strong · 80/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 11.8% over the last 12 months
Market Cap
$98.73B
P/E
7.42x
Forward P/E (est.)
5.3x
ROE
17.0%
Revenue Growth
43.7%
EPS Growth
96.2%
Profit Margin
17.2%
FCF Yield
21.4%
Debt / Equity
0.28x
ROIC
6.0%
Interest Coverage
11.27x
Current Ratio
1.09x
Dividend Yield
5.4%
Implied Growth (rev. DCF)
1.0%
Rating Score
80/100
Sanofi SA (SNY) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $98.73B.
In its latest reported year it generated about $47.12B in revenue and $8.44B in net profit.
Our model rates SNY Strong (80/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
76.5% average over the last 3 years
±2.9 pts around 72.9% across 10 years
grew in 6 of the last 9 year-over-year periods
positive in 10 of 10 years
6.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what SNY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. SNY trades near $43.76, around its 50-day average ($43.73) and 200-day average ($46.90). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 41 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. SNY's is $1.03 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month SNY found buyers near $40.89 (support) and sellers near $45.24 (resistance); its 52-week range is $40.89–$52.68. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
3.7%
Revenue moved from $36.51B in 2016 to $47.12B in 2025, a 2.9% compound annual growth rate. The most recent year grew a strong 43.7% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
77.2%
Operating Margin
14.5%
Net Margin
17.9%
ROE
17.0%
Sanofi SA keeps about 17.2% of each sales dollar as net profit, with a 77.2% gross margin and 14.5% operating margin. Return on equity is 17.0% and return on invested capital about 6.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$15.39B
Net Debt
$7.12B
Net Debt / EBITDA
1.04x
Debt / Equity
0.28x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 11.3x, with a current ratio of 1.1x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $15.39B of total debt against $8.27B of cash.
Operating CF
$11.61B
Free Cash Flow
$7.79B
FCF Margin
16.5%
In the latest year Sanofi SA produced about $11.61B of operating cash flow and $7.79B of free cash flow after capital spending. That is a free-cash-flow yield of about 21.4% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The payout is comfortably covered by cash the business actually generates, with a raise habit behind it.
Dividend yield
5.4%
Per share (latest FY)
$4.23
Total paid (latest FY)
$5.15B
History on record
10 years
dividend uses 66% of free cash flow
61% of net income paid out
total dividends increased 8 years in a row
no cuts in the last 10 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
7.42x
P/S
1.94x
P/B
1.41x
EV / EBITDA
—
SNY trades at 7.4x trailing earnings (about 5.3x on estimated forward earnings), 1.9x sales, and 1.4x book value. Reverse-engineering today's price implies the market expects roughly 1.0% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$264.51
Current price
$43.76
Starting FCF (latest 10-K)
$7.79B
Growth, years 1–5
20.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where SNY sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How SNY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), SNY ranks #3 of 324 by our overall rating. It trades at a discount versus the sector on earnings (7.4x P/E vs. 25.4x median) with a higher return on equity (17.0% vs. 14.1%) and faster revenue growth (43.7% vs. 7.6%).
P/E vs sector
7.4x
median 25.4x
ROE vs sector
17.0%
median 14.1%
Growth vs sector
43.7%
median 7.6%
Sector rank
#3
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $43.76 today · expected CAGR 22% – 34%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $67.85B | $97.70B | $140.69B | $202.59B | $291.73B |
| Net income | $12.21B | $17.59B | $25.32B | $36.47B | $52.51B |
| EPS | $5.41 | $7.79 | $11.22 | $16.16 | $23.27 |
| Share price (low) | $27.07 | $38.97 | $56.12 | $80.82 | $116.37 |
| Share price (high) | $43.30 | $62.36 | $89.80 | $129.31 | $186.20 |
| CAGR (low–high) | -38% / -1% | -6% / 19% | 9% / 27% | 17% / 31% | 22% / 34% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for SNY:
- Revenue is growing 43.7% a year, a sign of real demand.
- High net margins (17.2%) point to pricing power or efficiency.
- Strong return on equity (17.0%) shows capital is put to work well.
- Healthy free-cash-flow yield (~21.4%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
- Pays a 5.4% dividend on top of any price gains.
- Our model's overall read is Strong (80/100).
The case against SNY:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Sanofi SA is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 7.4x earnings, which our model scores Strong (80/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 29 Wall Street analysts covering SNY recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-5 pts of buy ratings).
Latest SEC Filings
SNY's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
SNY — frequently asked questions
Is SNY a good stock to buy?
We don't give buy or sell advice. Our model rates Sanofi SA Strong (80/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is SNY's rating on The Stocks School?
Sanofi SA currently scores 80/100 (Strong) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does SNY's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Sanofi SA's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for SNY calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this SNY analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell SNY. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.